Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

A Randomized Pilot Study of Online Hatha Yoga for Physical and Psychological Symptoms Among Survivors of Allogenic Bone Marrow Transplant
Eckert, Ryan , Huberty, Jennifer , Kurka, Jonathan , Palmer, Jeanne , Huberty, Jennifer , Laird, Breanne , Mesa, Ruben A.

Mayo Clinic

International Journal of Yoga Therapy | October 28, 2022 | Volume: 32 | Issue: 2022 | Pages: No page available

10.17761/2022-d-21-00047 | PMID 36305845 Get It

Abstract Bone marrow transplant (BMT) is a curative procedure for patients with hematological malignancies, hemoglobinopathies, and errors of inborn metabolism. Survivors are not without symptom burden. The purpose of this study was to assess the feasibility of a 12-week online yoga intervention compared to an educational control group in survivors of allogenic BMT. Participants were recruited nationally. Consenting participants were assigned to online yoga or a podcast control. Yoga and control group participants were instructed to complete 12 weeks of 60 minutes/week of online yoga and podcasts, respectively. Study participants were asked to complete online questionnaires at baseline (wk 0), midpoint (wk 6), postintervention (wk 12), and follow-up (wk 20). Feasibility benchmarks included > 70% satisfied with intervention and > 70% intending to continue participating in online yoga (acceptability); > 70% of participants achieving > 42 minutes/week of online yoga (demand); > 70% completing all four questionnaires (practicality); and at least small effect sizes of the intervention on Lee Symptom Score, physical function, fatigue, anxiety, sleep disturbance, social functioning, pain interference, depression, and quality of life as compared to control group (limited efficacy). Seventy-two participants consented and enrolled in the study (yoga group n = 33; podcast group n = 39). Of the yoga group participants, 54.5% (n = 19) completed the postintervention questionnaire, with 73.7% (n = 14) indicating they were satisfied/very satisfied and 15.8% (n = 3) likely/very likely to continue online yoga. Yoga participation averaged 31.98 minutes/week across 12 weeks. Both groups experienced a significant improvement in the Lee Symptom Score (6.2%–8.7% improvement from baseline) and depressive symptoms (5.3%–6.6% improvement from baseline). The yoga group experienced a significant reduction in pain (6.1% from baseline), and the podcast group experienced a significant reduction in fatigue (6.4% improvement from baseline). Online yoga was not found to be feasible to deliver to this population of survivors of BMT. However, there was satisfaction with online yoga among the majority of survivors of BMT, and beneficial effects were experienced in the yoga group on Lee Symptom Score, depressive symptoms, and pain. Future research is needed to enhance our understanding of barriers to online yoga participation for survivors of BMT and to determine its efficacy.
Anatomical Modeling at the Point of Care
Sears, Victoria A. , Morris, Jonathan M.

Mayo Clinic

Additive Manufacturing in Biomedical Applications | October 26, 2022 | Volume: No volume available | Issue: No issue available | Pages: 390-401

10.31399/asm.hb.v23a.a0006896 Get It

Abstract Bridging the gap between education and medical practice, centralized hospital-based 3D printing, or what is termed point-of-care (POC) manufacturing, has been rapidly growing in the United States as well as internationally. This article provides insights into the considerations and the current workflow of creating 3D-printed anatomical models at the POC. Case studies are introduced to show the complex range of anatomical models that can be produced while also exploring how patient care benefits. It describes the advanced form of communication in medicine. The advantages as well as pitfalls of using the patient-specific 3D-printed models at the POC are addressed, demonstrating the fundamental knowledge needed to create 3D-printed anatomical models through POC manufacturing.
Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization
Ono, Masafumi , Serruys, Patrick W. , Garg, Scot , Kawashima, Hideyuki , Gao, Chao , Hara, Hironori , Lunardi, Mattia , O’Leary, Neil , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Thuijs, Daniel J.F.M. , Mohr, Friedrich W., Davierwala, Piroze , Spertus, John A. , Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Piek, Jan J , Mack, Michael J , Holmes, David R , Thuijs, Daniel J F M , Spertus, John A , Cohen, David Jonathan , Onuma, Yoshinobu , Serruys, Patrick W , Garg, Scot , Wang, Rutao , Wykrzykowska, Joanna J. , Kappetein, A. Pieter , Noack, Thilo , Investigators, for the SYNTAX Extended Survival

Mayo Clinic

Circulation | October 24, 2022 | Volume: 146 | Issue: 17 | Pages: 1268-1280

10.1161/circulationaha.121.057021 | PMID 35862109 Get It

Background: Clinical and anatomical characteristics are often considered key factors in deciding between percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with complex coronary artery disease (CAD) such as left-main CAD or 3-vessel disease. However, little is known about the interaction between self-reported preprocedural physical/mental health and clinical outcomes after revascularization. Methods: This subgroup analysis of the SYNTAXES trial (SYNTAX Extended Survival), which is the extended follow-up of the randomized SYNTAX trial (Synergy Between PCI With Taxus and Cardiac Surgery) comparing PCI with CABG in patients with left-main CAD or 3-vessel disease, stratified patients by terciles of Physical (PCS) or Mental Component Summary (MCS) scores derived from the preprocedural 36-Item Short Form Health Survey, with higher PCS and MCS scores representing better physical and mental health, respectively. The primary end point was all-cause death at 10 years. Results: A total of 1656 patients with preprocedural 36-Item Short Form Health Survey data were included in the present study. Both higher PCS and MCS were independently associated with lower 10-year mortality (10-point increase in PCS adjusted hazard ratio, 0.84 [95% CI, 0.73–0.97]; P =0.021; in MCS adjusted hazard ratio, 0.85 [95% CI, 0.76–0.95]; P =0.005). A significant survival benefit with CABG over PCI was observed in the highest PCS (>45.5) and MCS (>52.3) terciles with significant treatment-by-subgroup interactions (PCS P interaction =0.033, MCS P interaction =0.015). In patients with both high PCS (>45.5) and MCS (>52.3), 10-year mortality was significantly higher with PCI compared with CABG (30.5% versus 12.2%; hazard ratio, 2.87 [95% CI, 1.55–5.30]; P =0.001), whereas among those with low PCS (≤45.5) or low MCS (≤52.3), there were no significant differences in 10-year mortality between PCI and CABG, resulting in a significant treatment-by-subgroup interaction ( P interaction =0.002). Conclusions: Among patients with left-main CAD or 3-vessel disease, patient-reported preprocedural physical and mental health status was strongly associated with long-term mortality and modified the relative treatment effects of PCI versus CABG. Patients with the best physical and mental health had better 10-year survival with CABG compared with PCI. Assessment of self-reported physical and mental health is important when selecting the optimal revascularization strategy. Registration: URL: https://www.clinicaltrials.gov ; SYNTAXES Unique identifier: NCT03417050. URL: https://www.clinicaltrials.gov ; SYNTAX Unique identifier: NCT00114972.
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn’s Disease
Chugh, Rishika , Neto, Manuel B. Braga , Fredrick, Thomas , Terdiman, Jonathan P., El‐Nachef, Najwa , Loftus, Edward V. , Mahadevan, Uma , Kane, Sunanda V. , Braga Neto, Manuel B , Fredrick, Thomas W , Loftus, Edward V , Mahadevan, Uma , Kane, S , Ramos, Guilherme Piovezani

Mayo Clinic

Journal of Crohn's and Colitis | October 22, 2022 | Volume: 17 | Issue: 4 | Pages: 504-512

10.1093/ecco-jcc/jjac157 | PMID 36272109 Get It

Abstract Background Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the management of Crohn’s disease [CD] in Phase 3 clinical trials. Aims Our goal was to describe our real-world experience with upadacitinib in CD. Methods This is a two-centre retrospective cohort study of adult patients with moderate to severe CD on upadacitinib. The primary outcome was clinical response and remission as determined by stool frequency and abdominal pain scores. Secondary endpoints included endoscopic response and remission as determined by change in Simple Endoscopic Score for CD. Outcomes were assessed at 3 months after starting upadacitinib and at the patient’s most recent follow-up. We further evaluated adverse events and dose-related response. Results A total of 45 CD patients received upadacitinib and were included in the safety analysis. Thirty-six patients received upadacitinib for CD, whereas nine received it for inflammatory arthritis [n = 8] or pyoderma [n = 1]. Thirty-three patients received upadacitinib for 3 months or longer and were included in the efficacy analysis. At the 3-month follow-up, 21 patients achieved clinical response [63.6%] and nine achieved clinical remission [27.2%]. At time of last follow-up, 23 patients had clinical response [69.7%], ten achieved clinical remission [30.3%] and four [28.6%] achieved endoscopic remission. Adverse events occurred in 12 patients [26.7%]. Two patients had a serious adverse event [4.5%] without associated mortality. Conclusion In this real-world cohort of highly refractory CD patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
Martin, Ting , Sun, Yilun , Malone, Shawn , Roach, Mack , Dearnaley, David P. , Pisansky, Thomas M. , Feng, Felix Y. , Sandler, Howard M. , Efstathiou, Jason A. , Syndikus, Isabel , Hall, Emma , Tree, Alison , Sydes, Matthew R. , Cruickshank, Claire, Roy, Soumyajit , Bolla, M. , Reijke, Theo de, Nabid, Abdenour , Carrier, Nathalie , Souhami, Luís, Guerrero, A., Álvarez, A. , Segundo, Carmen González‐San , Maldonado, Xavier , Romero, Tahmineh , Steinberg, Michael L. , Valle, Luca , Nickols, Nicholas G. , Shoag, Jonathan E. , Reiter, Robert E. , Jia, Angela Y. , García, Jorge A. , Spratt, Daniel E. , Kishan, Amar U. , Ma, Ting Martin , Dearnaley, David , Hall, Emma C , Tree, Alison C , Bolla, Michel , Maingon, Philippe , Alvarez, Ana , Gonzalez San-Segundo, Carmen , Steinberg, Michael L , Valle, Luca F , Shoag, Jonathan E , Zaorsky, Nicholas G , Spratt, Daniel E , Kishan, Amar U , Sandler, Howard M , Efstathiou, Jason A , Zapatero, A. , Rettig, Matthew B. , Zaorsky, Nicholas G.

Mayo Clinic

Journal of Clinical Oncology | October 21, 2022 | Volume: 41 | Issue: 4 | Pages: 881-892

10.1200/jco.22.00970 | PMID 36269935 Get It

PURPOSE The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer–specific mortality. RESULTS Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points ( P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer–specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis
Klamer, Brett , Brown, Paul D. , Cerhan, Jane H. , Anderson, S. Keith , Carrero, Xiomara W., Whitton, Anthony , Greenspoon, Jeffrey , Ashman, Jonathan B. , Bahary, Jean-Paul , Urbanic, James J., Barker, Fred G., Farace, Elana, Khuntia, Deepak , Buckner, Jan C. , Laack, Nadia N I, Palmer, Joshua D. , Ballman, Karla V. , Parney, Ian F. , Laack, Nadia N. , Hadjipanayis, Costas G. , Giannini, Caterina , Galanis, Evanthia , Roberge, David

Mayo Clinic

JAMA Oncology | October 20, 2022 | Volume: 8 | Issue: 12 | Pages: 1809

10.1001/jamaoncol.2022.5049 | PMID 36264568 Get It

Importance Long-term outcomes of radiotherapy are important in understanding the risks and benefits of therapies for patients with brain metastases. Objective To determine how the use of postoperative whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) is associated with quality of life (QOL), cognitive function, and intracranial tumor control in long-term survivors with 1 to 4 brain metastases. Design, Setting, and Participants This secondary analysis of a randomized phase 3 clinical trial included 48 institutions in the US and Canada. Adult patients with 1 resected brain metastases but limited to those with 1 to 4 brain metastasis were eligible. Unresected metastases were treated with SRS. Long-term survivors were defined as evaluable patients who lived longer than 1 year from randomization. Patients were recruited between July 2011 and December 2015, and data were first analyzed in February 2017. For the present study, intracranial tumor control, cognitive deterioration, QOL, and cognitive outcomes were measured in evaluable patients who were alive at 12 months from randomization and reanalyzed in June 2017. Interventions Stereotactic radiosurgery or WBRT. Main Outcomes and Measures Intracranial tumor control, toxic effects, cognitive deterioration, and QOL. Results Fifty-four patients (27 SRS arm, 27 WBRT arm; female to male ratio, 65% vs 35%) were included for analysis with a median follow-up of 23.8 months. Cognitive deterioration was less frequent with SRS (37%-60%) compared with WBRT (75%-91%) at all time points. More patients declined by 2 or more standard deviations (SDs) in 1 or more cognitive tests for WBRT compared with SRS at 3, 6, and 9 months (70% vs 22%, 46% vs 19%, and 50% vs 20%, respectively). A 2 SD decline in at least 2 cognitive tests was associated with worse 12-month QOL in emotional well-being, functional well-being, general, additional concerns, and total scores. Overall QOL and functional independence favored SRS alone for categorical change at all time points. Total intracranial control for SRS alone vs WBRT at 12 months was 40.7% vs 81.5% (difference, −40.7; 95% CI, −68.1% to −13.4%), respectively. Data were first analyzed in February 2017. Conclusions and Relevance The use of SRS alone compared with WBRT resulted in less cognitive deterioration among long-term survivors. The association of late cognitive deterioration with WBRT was clinically meaningful. A significant decline in cognition (2 SD) was associated with overall QOL. However, intracranial tumor control was improved with WBRT. This study provides detailed insight into cognitive function over time in this patient population. Trial Registration ClinicalTrials.gov Identifier: NCT01372774 ; ALLIANCE/CCTG: N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group)
The many faces of globular glial tauopathy: A clinical and imaging study
Buciuc, Marina , Koga, Shunsuke , Pham, Nha Trang Thu, Ali, Farwa , Graff‐Radford, Jon, Lowe, Val J. , Nguyen, Aivi T. , Reichard, Ross R., Petersen, Ronald C. , Whitwell, Jennifer L. , Josephs, Keith A. , Whitwell, Jennifer , Josephs, Keith A , Koga, Shunsuke , Buciuc, Marina , Nguyen, Aivi T , Duffy, Joseph R. , Knopman, David S. , Boeve, Bradley F. , Graff‐Radford, Jonathan , Botha, Hugo , Dickson, Dennis W.

Mayo Clinic

European Journal of Neurology | October 18, 2022 | Volume: 30 | Issue: 2 | Pages: 321-333

10.1111/ene.15603 | PMID 36256511 Get It

AbstractBackgroundGlobular glial tauopathy (GGT) has been associated with frontotemporal dementia syndromes; little is known about the clinical and imaging characteristics of GGT and how they differ from other non‐globular glial 4‐repeat tauopathies (N4GT) such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD).MethodsFor this case–control study the Mayo Clinic brain banks were queried for all cases with an autopsy‐confirmed diagnosis of GGT between 1 January 2011 and 31 October 2021. Fifty patients with N4GT (30 PSP, 20 CBD) were prospectively recruited and followed by the Neurodegenerative Research Group at Mayo Clinic, Minnesota. Magnetic resonance imaging was used to characterize patterns of gray/white matter atrophy, MR‐parkinsonism index, midbrain volume, and white matter hyperintensities.18F‐Fluorodeoxyglucose‐, 11C Pittsburg compound‐, and 18F‐flortaucipir‐positron emission tomography scans were reviewed.ResultsTwelve patients with GGT were identified: 83% were women compared to 42% in NG4T (p = 0.02) with median age at death 76.5 years (range: 55–87). The most frequent clinical features were eye movement abnormalities, parkinsonism, behavioral changes followed by pyramidal tract signs and motor speech abnormalities. Lower motor neuron involvement was present in 17% and distinguished GGT from NG4T (p = 0.035). Primary progressive apraxia of speech was the most frequent initial diagnosis (25%); 50% had a Parkinson‐plus syndrome before death. Most GGT patients had asymmetric frontotemporal atrophy with matching hypometabolism. GGT patients had more gray matter atrophy in temporal lobes, normal MR‐parkinsonism index, and larger midbrain volumes.ConclusionsFemale sex, lower motor neuron involvement in the context of a frontotemporal dementia syndrome, and asymmetric brain atrophy with preserved midbrain might be suggestive of underlying GGT.
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers
Hogenson, Tara L. , Phillips, William J. , Toruner, Merih Deniz , Li, Jing , Horn, Isaac P. , Kennedy, Devin J. , Almada, Luciana L. , Marks, David L. , Törüner, Murat , Sigafoos, Ashley N. , Koenig-Kappes, Amanda N., Olson, Rachel , Tolosa, Ezequiel J. , Bleeker, Jonathan , Barrett, Michael T. , Boyum, James H. , Kipp, Benjamin R. , Hanson, Temperance J. Scheffler, Petersen, Gloria M. , Dasari, Surendra , Oberg, Ann L. , Truty, Mark J. , Levy, Michael J. , Zhu, Mojun, Billadeau, Daniel D. , Adjei, Alex A. , Dusetti, Nelson , Iovanna, J., Bekaii‐Saab, Tanios , Fernández-Zapico, Martín E. , Toruner, Merih D., Doles, Jason D. , Bekaii-Saab, Tanios S , Toruner, Merih D , Xie, Hao , Phillips, William J. , Carr, Ryan M , Koenig-Kappes, A., Zhang, Cheng , Li, Hu , Mahipal, Amit , Hubbard, Joleen M. , Graham, Rondell P. , Wee, Wen

Mayo Clinic

JCI Insight | October 18, 2022 | Volume: 7 | Issue: 22 | Pages: No page available

10.1172/jci.insight.158060 | PMID 36256477 Get It

BACKGROUND A patient-derived organoid (PDO) platform may serve as a promising tool for translational cancer research. In this study, we evaluated PDO’s ability to predict clinical response to gastrointestinal (GI) cancers. METHODS We generated PDOs from primary and metastatic lesions of patients with GI cancers, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and cholangiocarcinoma. We compared PDO response with the observed clinical response for donor patients to the same treatments. RESULTS We report an approximately 80% concordance rate between PDO and donor tumor response. Importantly, we found a profound influence of culture media on PDO phenotype, where we showed a significant difference in response to standard-of-care chemotherapies, distinct morphologies, and transcriptomes between media within the same PDO cultures. CONCLUSION While we demonstrate a high concordance rate between donor tumor and PDO, these studies also showed the important role of culture media when using PDOs to inform treatment selection and predict response across a spectrum of GI cancers. TRIAL REGISTRATION Not applicable. FUNDING The Joan F. & Richard A. Abdoo Family Fund in Colorectal Cancer Research, GI Cancer program of the Mayo Clinic Cancer Center, Mayo Clinic SPORE in Pancreatic Cancer, Center of Individualized Medicine (Mayo Clinic), Department of Laboratory Medicine and Pathology (Mayo Clinic), Incyte Pharmaceuticals and Mayo Clinic Hepatobiliary SPORE, University of Minnesota-Mayo Clinic Partnership, and the Early Therapeutic program (Department of Oncology, Mayo Clinic).
Physiological Offset Parameters of the Adult Shoulder Joint—A MRI Study of 800 Patients
Meier, Marc‐Pascal , Brandt, Lars Erik , Saul, Dominik , Roch, Paul Jonathan , Klockner, Friederike Sophie , Hosseini, Ali , Lehmann, Wolfgang , Hawellek, Thelonius, Saul, Dominik , Hosseini, Ali Seif Amir

Mayo Clinic

Diagnostics | October 17, 2022 | Volume: 12 | Issue: 10 | Pages: 2507

10.3390/diagnostics12102507 | PMID 36292196 Get It

Background: Humeral offset (HO) and glenoidal offset (GO) are important morphological parameters in diagnostics and therapy for shoulder pathologies. However, physiological reference values have not yet been sufficiently determined. The aim of the present study was to establish physiological reference values for shoulder offset parameters (SOPs). Methods: MRI images of the shoulder joints of 800 patients (mean age: 50.13 years [±16.01]) were analysed retrospectively. HO, GO, lateral glenoidal humeral offset (LGHO), humeral shaft axis offset (HAO) and cortical offset (CO) were measured. SOPs were examined for associations with age, gender, side and osteoarthritis. Results: The mean HO was 26.19 (±2.70), the mean GO was 61.79 (±5.67), the mean LGHO was 54.49 (±4.69), the mean HAO was 28.17 (±2.82) and the mean CO was 16.70 (±3.08). For all SOPs, significantly higher values were measured in male shoulders. There was a significantly (p < 0.001) higher mean value for HO, GO and LGHO in right shoulders. There was a significant correlation between age and LGHO, and HAO and CO, but not between age and HO or GO. Shoulders with osteoarthritis and non-osteoarthritis did not differ in the mean value of HO, GO, LGHO and HAO, except for CO (p = 0.049). Conclusion: Reference values for SOPs in the adult shoulder joint were determined for the first time. Significant gender-specific differences were found for all measured SOPs. In addition, it was seen that for some SOPs, the joint side and the patient’s age has to be taken into account in shoulder diagnostics and surgery.
Incidence and risk factors for major bleeding events in atrial fibrillation patients on direct oral anticoagulant therapy: data from the National Patient-Centered Clinical Research Network
Arps, K, Harrington, Josephine , Wu, An-Bang , Raj, V, Steinberg, B A, Mundl, Hardi , Viethen, Thomas , Granger, C. B., Piccini, Jonathan P. , Patel, Manesh R. , Carnicelli, Anthony , Chiswell, Karen , Chamberlain, Alanna M. , Chrischilles, Elizabeth A. , Jones, W. Schuyler , Steinberg, Benjamin A. , Granger, Christopher B.

Mayo Clinic

European Heart Journal | October 15, 2022 | Volume: 43 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehac544.624 Get It

Abstract Background Direct oral anticoagulation (DOACs) prevent stroke in patients with atrial fibrillation (AF) and have a superior safety profile compared with vitamin K antagonists (VKA). Yet, better definition of incidence and risk factors for major bleeding associated with DOACs in clinical practice may be important given emerging stroke prevention technologies, both pharmacologic and nonpharmacologic. Purpose To describe the incidence of and risk factors for major bleeding in individuals with AF on DOAC therapy. Methods We reviewed electronic health record data for two patient cohorts with AF prescribed DOACs: (1) Duke University Health System (DUHS) (2010–2018) and (2) Sites within the Patient-Centered Clinical Research Network (PCORnet) (2015–2019) which had ≥6 years assimilated data from both inpatient and outpatient encounters (7 sites). In each cohort, we assessed the 5-year incidence of major bleeding events defined as hospitalization for intracranial hemorrhage, or hospitalization for gastro-intestinal bleeding or procedure to control bleeding accompanied by transfusion within ±7 days or death within 30 days. Multivariable Fine-Gray proportional hazards modeling in each cohort was performed to evaluate independent risk factors for major bleeding on DOAC therapy. Results The cohorts included 10,625 patients (DUHS) and 58,321 patients (PCORnet) with AF. Major bleeding events occurred within 5 years of diagnosis in 639 (7.9%) of DUHS patients and 2568 (6.6%) of PCORnet patients (Table 1). The DUHS model predicted time to first major bleeding event with a C-index of 0.756 (95% CI 0.737, 0.775) and the PCORNet model had a c-index of 0.745 (0.736, 0.755) (Table 2). Independent factors associated with major bleeding consistent across both models (p&lt;0.001 in PCORnet for all unless noted) were higher CHA2DS2-VASc scores, lower eGFR, anemia (HR per 1-point increase in hemoglobin up to 12 g/dL 0.79 [0.76, 0.82]), prior major bleeding (HR 2.70 [2.22, 3.30]), cancer (HR 1.23 [1.12, 1.36]), recent cardiac surgery (HR 0.70 [0.51, 0.97]; p=0.030), alcohol use (HR 1.56 [1.29, 1.88]), aspirin use (HR 1.44 [1.32, 1.57]), and selective serotonin reuptake inhibitor use (HR 1.30 [1.19, 1.42]). Conclusions Across a large and geographically diverse contemporary population, risk of bleeding on DOAC for stroke prevention in AF remains a frequent and important clinical problem. There is an unmet need for stroke prevention therapies with improved safety profiles. We identified risk factors for major bleeding events on DOAC therapy, some of which are not represented in traditional risk scores, which may inform shared decision making for stroke prevention. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Bayer Pharmaceuticals